What is Vertex Pharmaceuticals Incorporated's (VRTX) StockRank?

MoatMap's StockRank for Vertex Pharmaceuticals Incorporated (VRTX) is 76/100, with a Buy signal. This is a composite score combining Quality (78), Value (28), and Momentum (63) factor ranks across MoatMap's 20,000+ stock universe.

Does Vertex Pharmaceuticals Incorporated have an economic moat?

Vertex Pharmaceuticals Incorporated (VRTX) has a Quality factor score of 78/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Vertex Pharmaceuticals Incorporated a buy, hold, or sell?

MoatMap's current signal for Vertex Pharmaceuticals Incorporated (VRTX) is Buy, based on a StockRank of 76/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Vertex Pharmaceuticals Incorporated in?

Vertex Pharmaceuticals Incorporated (VRTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

VRTX

BUYFLAG

Vertex Pharmaceuticals Incorporated · Healthcare · United States · $121.2B · Avg Vol: $861M/d

StockRank

Get insider-trade alerts

P/E (TTM)

28.0x

ROE

24.2%

D/E

0.1x

Dividend %

—

AI CONVICTION THESIS

Vertex Pharmaceuticals has exceptional quality Q78 and momentum M65 with a buyback, but value at V28 is well below the calibrated floor, and insiders sold, so stage one fails.

COMPANY DESCRIPTION

Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, primarily cystic fibrosis (CF). It holds a dominant market position in CF treatments with proprietary, highly effective therapies that address the disease's underlying causes. Vertex is a leader in precision medicines, utilizing deep scientific expertise to target genetic mutations and expanding into other therapeutic areas.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	8.9B	9.9B	11.0B	12.0B	10.4%	12.2B	13.1B	14.4B	9.4%
EPS	12.97	14.05	-2.08	15.46	6.0%	16.84	15.95	17.93	7.7%
Shares	257.0M	257.7M	256.9M	254.0M	-1.2%	253.8M	—	—	—
Debt	899.7M	808.4M	1.7B	2.0B	31.2%	2.0B	—	—	—
Equity	13.9B	17.6B	16.4B	18.7B	10.3%	—	—	—	—
Op CF	4.1B	3.5B	-492.6M	3.6B	-4.2%	4.2B	—	—	—
Inv CF	-321.1M	-3.1B	-3.8B	-945.4M	—	—	—	—	—
Fin CF	-67.7M	-562.2M	-1.5B	-2.3B	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+5.6%

SMA 50SMA 200

$477.10

RSI (14)

47.4

52W High

$533.67

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

23.2%92.6

ROE

24.2%91.6

GP/Assets

25.9%59.8

Op. Margin

38.1%96.1

FCF/Assets

14.5%88.7

Piotroski

668.3

Int. Cover

50.0x88.8

D/E Ratio

0.10x62.6

Current Ratio

3.02x54.0

Value

P/E (TTM)

28.0x39.8

EV/EBITDA

23.3x24.9

P/FCF

32.7x28.6

P/B

6.2x21.2

P/S

9.8x26.9

Div Yield

—N/A

Momentum

52W High %

89%87.1

RS 6M

-8%67.5

SMA 50/200

1.03x71.5

EPS Rev 4W

-0.7%31.0

EPS Rev 12W

-2.1%33.4

EPS Improve

+27%40.0

Q Growth

60%78.1

FUNDAMENTALS

Market Cap

$121.2B

P/E (Forward)

22.1x

Gross Margin

54.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VRTX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
VRTX	Vertex Pharmaceuticals Incorporated(you)	$121.2B	76	BUY
REGN.MX	Regeneron Pharmaceuticals, Inc.	$64.9B	78	BUY
ARGX	argenx SE	$57.1B	70	BUY
688235.SS	BeOne Medicines AG	$46.1B	78	BUY
UCB.BR	UCB SA	$56.0B	64	HOLD
RPRX	Royalty Pharma plc	$33.9B	70	BUY
0R2B.L	Danaher Corporation	$138.7B	45	HOLD
0QNO.L	Lonza Group AG	$47.0B	61	HOLD
0HAV.L	Agilent Technologies, Inc.	$36.7B	60	HOLD
GMAB.CO	Genmab A/S	$15.9B	74	BUY

Peer medians: ROE 2.0% · P/E 23.4x · Gross margin 50.1%

Vertex Pharmaceuticals Incorporated (VRTX): Stock Score Summary

Vertex Pharmaceuticals Incorporated (VRTX) has a MoatMap StockRank of 76/100 based on Quality (78/100), Value (28/100), and Momentum (63/100) factor scores. The current signal is BUY. Vertex Pharmaceuticals has exceptional quality Q78 and momentum M65 with a buyback, but value at V28 is well below the calibrated floor, and insiders sold, so stage one fails.

Key Financial Metrics

Price	$477.10
Market Cap	$121.2B
P/E (TTM)	27.95
P/E (Forward)	22.06
Price/Book	6.18
Return on Equity	24.2%
Return on Invested Capital	23.2%
Debt/Equity	0.10x
Gross Margin	54.4%
Operating Margin	38.1%
Revenue Growth	7.8%
Free Cash Flow	$3.7B

Vertex Pharmaceuticals Incorporated operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Vertex Pharmaceuticals Incorporated’s (VRTX) StockRank?: MoatMap’s StockRank for Vertex Pharmaceuticals Incorporated (VRTX) is 76/100, with a Buy signal. It is a composite of Quality (78), Value (28), and Momentum (63) factor ranks across MoatMap’s 20,000+ stock universe.
Does Vertex Pharmaceuticals Incorporated have an economic moat?: Vertex Pharmaceuticals Incorporated (VRTX) has a Quality factor score of 78/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Vertex Pharmaceuticals Incorporated a buy, hold, or sell?: MoatMap’s current signal for Vertex Pharmaceuticals Incorporated (VRTX) is Buy, based on a StockRank of 76/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Vertex Pharmaceuticals Incorporated in?: Vertex Pharmaceuticals Incorporated (VRTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).